Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKinsey
Express Scripts
Mallinckrodt
Harvard Business School

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR PEGLOTICASE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for pegloticase

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00675103 ↗ Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients Completed Savient Pharmaceuticals Phase 3 2008-05-01 The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry. This study is limited to four study centers in the US.
NCT01739660 ↗ Study to Assess Pegloticase (KRYSTEXXA┬«) in Patients on Hemodialysis Completed Savient Pharmaceuticals Phase 1 2012-12-01 This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase administered to hemodialysis patients. A single dose of pegloticase will be administered intravenously to male or female hemodialysis patients (N = 12) starting 3 hour prior to dialysis. The study consists of a Screening Period, a Treatment Period, and Follow up Period.
NCT02598596 ↗ Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect Completed IND 2 Results LLC Phase 2 2015-12-01 The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level <6 mg/dL, in patients with chronic, refractory gout.
NCT02598596 ↗ Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect Completed Ampel BioSolutions, LLC Phase 2 2015-12-01 The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level <6 mg/dL, in patients with chronic, refractory gout.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for pegloticase

Condition Name

Condition Name for pegloticase
Intervention Trials
Gout 1
Gout Chronic 1
Asymptomatic Hyperuricemia 1
Hematopoietic and Lymphoid Cell Neoplasm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for pegloticase
Intervention Trials
Hyperuricemia 2
Kidney Diseases 2
Gout 2
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for pegloticase

Trials by Country

Trials by Country for pegloticase
Location Trials
United States 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for pegloticase
Location Trials
Maryland 3
Alabama 3
Pennsylvania 2
Ohio 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for pegloticase

Clinical Trial Phase

Clinical Trial Phase for pegloticase
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for pegloticase
Clinical Trial Phase Trials
Completed 5
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pegloticase

Sponsor Name

Sponsor Name for pegloticase
Sponsor Trials
Savient Pharmaceuticals 2
M.D. Anderson Cancer Center 1
First Affiliated Hospital Bengbu Medical College 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for pegloticase
Sponsor Trials
Industry 6
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
Merck
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.